Want to see AVBP full AI Analyst Report?
AVBP Stock Chart & Stats
$29.64
$0.14(0.52%)
At close: 4:00 PM EST
$29.64
$0.14(0.52%)
Day’s Range― - ―
52-Week Range$16.10 - $35.83
Previous CloseN/A
Volume49.09K
Average Volume (3M)663.32K
Market Cap
$1.57B
Enterprise Value$1.40B
Total Cash (Recent Filing)$326.38M
Total Debt (Recent Filing)$419.00K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 18, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding46,574,930
10 Day Avg. Volume455,313
30 Day Avg. Volume663,322
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.63
Forecast
1Y Price Target
$43.08Price Target Upside45.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt and a materially larger asset base reduce short-term refinancing risk and provide operational runway for clinical programs. This durable capital structure gives strategic optionality to fund trials, pursue partnerships, or withstand trial timelines before revenue realization.
At-the-Market Funding ProgramAn active $250M ATM program formalizes access to public equity, offering structural financing flexibility to support clinical development and regulatory activities. This reduces the need for emergency financings and smooths capital planning, though it does not eliminate dilution risk.
Focused Oncology PipelineA concentrated pipeline with a lead EGFR inhibitor targets a defined genetic subset of NSCLC, providing clear clinical and regulatory milestones. Success here would create a durable revenue stream and competitive niche; the program's focus sharpens resource allocation and partner/discovery appeal.
Bears Say
Pre-Revenue With Widening LossesSizable and increasing net losses reflect ongoing investment in trials without product revenue. Over multiple years this erodes returns and necessitates continued funding; long-term viability depends on clinical success or new funding sources rather than operational cash flow.
Persistent Negative Cash Flow / Cash BurnConsistently negative operating and free cash flow shows real cash consumption to progress development. This structural cash burn forces reliance on financing rounds or program cuts if milestones slip, constraining sustainable investment and increasing execution risk over the medium term.
Reliance On Public Equity / Dilution RiskThe company's funding strategy depends materially on equity markets as a primary capital source. While ATM access provides flexibility, persistent issuance dilutes shareholders and ties long-term funding capacity to market conditions, which can constrain strategic options if access tightens.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $16.10 and its highest was $35.83 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.57B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 34 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on May 11, 2026. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.895 by -$0.065.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.99.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 46,574,930 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.895. Following the earnings report the stock price went down -0.172%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.08 (45.35% Upside)
$43.08 (45.35% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 70%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 35.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.52%
12-Months-Change
Fundamentals
Return on Equity
-48.98%
Trailing 12-Months
Asset Growth
62.09%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$43.08
▲(45.35% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
9.57% Insiders
12.10% Mutual Funds
0.21% Other Institutional Investors
66.86% Public Companies and
Individual Investors